Nuclide nano hydrogel microneedle as well as preparation method and application thereof

By combining photothermal treatment with 32P and Ag2S@Ca32P nanoparticles in nuclide nanohydrogel microneedle, the problems of postoperative recurrence and infection of melanoma were solved, and efficient treatment of melanoma and wound healing were achieved, which significantly improved the Patient survival rate.

CN118987290AActive Publication Date: 2024-11-22XIANGYA HOSPITAL CENT SOUTH UNIV

Patent Information

Application Number
CN202411099542.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

The problem of difficult healing of postoperative recurrence and wound infections in melanoma, especially due to recurrence and healing difficulties caused by bacterial infection, blood circulation disorders and flap transplantation problems. The prior art is difficult to effectively remove residual infiltrating tumor cells and control infection.

Method used

Develop a nuclide nanohydrogel microneedle equipped with 32P radionuclides and Ag2S@Ca32P nanoparticles. Through radionuclide irradiation and photothermal treatment, it combines the antibacterial, hemostasis and promotion of cell attachment of methacrylated gelatin. to achieve local efficient delivery and antibacterial effects.

Benefits of technology

Effectively inhibit postoperative recurrence and infection of melanoma, promote wound healing, DNA breakage caused by radionuclides and thermal ablation of photothermal therapy, significantly reduce the risk of tumor recurrence and the degree of infection, and improve the survival rate of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987290A_ABST
    Figure CN118987290A_ABST
Patent Text Reader

Abstract

The invention provides a nuclide nano hydrogel microneedle and a preparation method and application thereof, and belongs to the field of nano biological medicines.The nuclide nano hydrogel microneedle comprises a needle tip layer and a substrate layer, the needle tip layer is formed by loading a nuclide nano-drug to a methacrylated gelatin microneedle tip, the nuclide nano-drug comprises Ag2S nanoparticles and radionuclide 32P labeled calcium phosphate, and the substrate layer is formed by loading the nuclide nano-drug to the methacrylated gelatin microneedle tip. Ag2S and Ca32P nanoparticles are formed through a biological mineralization reaction, and a substrate layer is a substrate matrix and comprises hyaluronic acid; ag2S and Ca32P in the nuclide nano-drug hydrogel microneedle prepared by the scheme can respond to a weak acid environment of tumors to release Ag2S nanoparticles, under the irradiation of near-infrared light, the photothermal conversion efficiency of the Ag2S nanoparticles can effectively kill bacteria, meanwhile, the low-oxygen environment of the tumors is effectively improved, the treatment effect of nuclides is enhanced, and the nuclide nano-drug hydrogel microneedle has a good application prospect. The antibacterial and wound healing promoting effects are achieved in melanoma defect repair, and tumor growth and tumor recurrence can be inhibited to the maximum extent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of nano-biomedicine, and specifically relates to a nuclide nano-hydrogel microneedle and a preparation method and application thereof. Background Art

[0002] Melanoma is a highly malignant tumor. It only accounts for 4% of skin cancer cases, but it causes more than 75% of skin cancer deaths. The main cause of melanoma is the uncontrolled proliferation of melanocytes in the basal layer of the epidermis. Its occurrence and development are the result of the combined action of multiple factors such as genes and environment. The guidelines of the Chinese Society of Clinical Oncology point out that patients with localized melanoma (stage 0-stage II) can be cured by surgical resection of the primary lesion. However, surgical treatment is still accompanied by a certain risk of postoperative recurrence. The recurrence rates of patients with stage IB and stage II melanoma are 8% and 29%, respectively, and the recurrence rate and mortality rate of patients are positively correlated. There are several main risk factors for local recurrence of tumors: First, positive surgical margins. Second, the depth of tumor invasion of the skin. If the depth of tumor infiltration is greater than 4mm, even if the tumor is removed, the patient may relapse in a relatively short period of time. Third, the onset of melanoma is mostly located in the limbs and mucosa, and it is difficult to completely remove the tumor lesions through surgical operations; and the residual microsatellite lesions and microinfiltration of tumor cells after surgery can still lead to local recurrence of melanoma. Fourth, intraoperative bleeding can also cause tumor cells to spread into the blood, thereby increasing the level of circulating tumor cells in the body and increasing the risk of postoperative recurrence. The above shows that postoperative recurrence in patients with localized melanoma is an urgent problem to be solved. In addition, the difficulty of wound healing after surgery in patients with melanoma is also a thorny problem in treatment. The factors that affect postoperative wound healing in patients with melanoma are mainly the following three aspects: bacterial infection, blood circulation disorders, and flap transplantation problems. Among them, bacterial infection is the most common pathogenic factor in the wound healing process, and the abuse of antibiotics will lead to the production of drug-resistant bacteria, further aggravating the degree of wound infection. In addition, whether the patient relapses after surgery is also related to whether the wound is infected or not. The tumor recurrence rate of patients with postoperative wound infection is significantly increased, and patients who receive neoadjuvant therapy after surgery can prolong the recurrence-free survival rate to a certain extent and reduce the risk of recurrence. Therefore, in order to improve the survival rate of patients with malignant melanoma, it is urgent to establish a treatment strategy that effectively removes residual infiltrating tumor cells, controls infection, and accelerates wound repair.

[0003] With the rapid development of nuclear medicine, the use of radionuclides to treat tumors has become a new, safer and more efficient treatment method. Radionuclide therapy refers to the use of radionuclides (such as 32P, 90Y, etc.) with appropriate half-life, radiation distance and radiation energy to emit rays with high linear transfer energy to kill tumors. Among them, 32P is widely used in the treatment of superficial capillary hemangiomas, scars, etc. on the skin due to its advantages such as longer range (up to 8mm), larger energy (1.7MeV), and suitable half-life (14 days). And studies have shown that 32 The β rays released by P are more likely to cause double-strand breaks in tumor cell DNA and prevent replication than the same dose of high-energy extracellular electrons (such as 90Y), and it is a potential new anti-tumor drug. 32 P is used in the treatment of melanoma and exerts an anti-tumor effect on postoperative recurrence of melanoma.

[0004] To address the problems of postoperative infection and difficult wound healing in melanoma, there are currently a variety of emerging treatment methods such as photothermal therapy (PTT). PTT is a minimally invasive treatment method that converts near infrared radiation (NIR) into thermal energy (45°C) through a photothermal agent to thermally ablate bacteria or tumor cells without damaging surrounding tissues. Compared with traditional antibacterial methods, it has the characteristics of non-invasiveness, no drug resistance, few side effects, and high sterilization rate. So far, a series of photothermal nanomaterials with excellent performance have been developed.

[0005] However, how to effectively and locally deliver these drugs to the tumor site has always been one of the bottlenecks in biomedicine. Developing a radionuclide nanomaterial that can prevent postoperative recurrence and infection of melanoma has good clinical application value. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a radionuclide nano hydrogel microneedle and its preparation method and application, and constructs a radionuclide nano drug delivery system that can resist postoperative recurrence and infection of melanoma. 32 P can break the double-stranded DNA of tumor cells and play an anti-tumor recurrence role; for the problem of postoperative infection of melanoma, Ag2S@Ca in the microneedle tip 32P nanoparticles can release Ag2S nanoparticles in response to the slightly acidic environment of the tumor, and play an antibacterial role through the heat generated by near-infrared light irradiation; and the antibacterial, hemostatic, and cell adhesion-promoting effects of the microneedle tip component, gelatin methacrylate (GelMA), further promote wound healing. The radionuclide nanomedicine hydrogel microneedle can inhibit postoperative recurrence and infection of melanoma through radionuclide internal irradiation combined with photothermal therapy, and effectively promote wound healing.

[0007] To achieve the above object, the present invention first provides a radionuclide nano-hydrogel microneedle, wherein the radionuclide nano-hydrogel microneedle comprises a base layer and a needle tip layer, wherein the needle tip layer is composed of methacrylated gelatin loaded with radionuclide nano-drug Ag2S@Ca 32 P, the nuclide nanomedicine Ag2S@Ca 32 P includes core Ag2S nanoparticles, radionuclides 32 P-labeled calcium phosphate and bovine serum albumin coat.

[0008] Preferably, the needle length of the nuclide nano-hydrogel microneedle is 550 μm, and the diameter of the base layer is 9 mm.

[0009] Based on a general inventive concept, the present invention also provides a method for preparing a nuclide nano-hydrogel microneedle, comprising the following steps:

[0010] S1, bovine serum albumin was dissolved in ultrapure water, and AgNO3 was added after sonication and stirred to mix well. After adjusting the pH to 12, Na2S·9H2O was added and heated and stirred, and then incubated overnight, and dialyzed to obtain Ag2S nanoparticles;

[0011] S2, dispersing bovine serum albumin and the Ag2S nanoparticles obtained in step S1 into a mixture of ultrapure water and sugar-free DMEM, and adding phosphorus [ 32 P] acid sodium salt solution, CaCl2, incubate overnight and centrifuge, collect the precipitate and re-dissolve by ultrasonication 32 P-labeled Ag2S@Ca 32 P nanoparticles;

[0012] S3, add methacrylic gelatin to the photoinitiator to prepare methacrylic gelatin solution, heat in a light-proof water bath to dissolve, and then add Ag2S@Ca 32 P nanoparticles were dissolved in methacrylated gelatin solution, injected into the microneedle mold, centrifuged and vacuumed, and then dried, and the needle tip was cured by UV;

[0013] S4. Inject the base matrix into the microneedle mold with the needle tip solidified as the base layer, centrifuge and vacuumize, then dry, and demold to obtain the nuclide nano-hydrogel microneedle.

[0014] Preferably, the molar ratio of AgNO3, Na2S·9H2O and CaCl2 is 1:2:1; the phosphorus [ 32 The radioactivity concentration of the sodium salt solution of 1 μg / mL was 1 mCi / mL.

[0015] Preferably, the temperature of the heating and stirring in S1 is 55°C, the time is 4 hours, and the temperature of the overnight incubation is 37°C.

[0016] Preferably, the incubation temperature in S2 is 37°C.

[0017] Preferably, the photoinitiator in S3 is LAP with a concentration of 0.25%, the mass concentration of the methacrylated gelatin solution is 20%, the water bath heating temperature is 60° C., the time is 30 minutes, and the drying time is 24 hours.

[0018] Preferably, the base matrix in S4 comprises a hyaluronic acid solution with a mass concentration of 50%.

[0019] Preferably, the molecular weight of the hyaluronic acid is 10KDa.

[0020] Based on a general inventive concept, the present invention also provides an application of a radionuclide nano-hydrogel microneedle in the preparation of a drug for inhibiting melanoma growth and postoperative recurrence, wherein the drug needs to be combined with near-infrared light irradiation.

[0021] Based on a general inventive concept, the present invention also provides an application of a radionuclide nano-hydrogel microneedle in the preparation of a drug for preventing wound infection and promoting wound healing, wherein the drug needs to be combined with near-infrared light irradiation.

[0022] The mechanism of action of the nuclide nanohydrogel microneedles prepared in this scheme is as follows:

[0023] To address the problem of postoperative recurrence of melanoma, the microneedle contains 32 P can break the double-stranded DNA of tumor cells and play an anti-tumor recurrence role; for the problem of postoperative infection of melanoma, Ag2S@Ca in the microneedle tip 32 P nanoparticles can release Ag2S nanoparticles in response to the slightly acidic environment of the tumor, and play an antibacterial role through the heat generated by near-infrared light irradiation; and the antibacterial, hemostatic, and cell adhesion-promoting effects of the microneedle tip component, gelatin methacrylate (GelMA), further promote wound healing. The radionuclide nanomedicine hydrogel microneedle can inhibit postoperative recurrence and infection of melanoma through radionuclide internal irradiation combined with photothermal therapy, and effectively promote wound healing.

[0024] Under the irradiation of near-infrared light, Ag2S releases Ag +The inherent antibacterial activity and the high temperature generated by PTT therapy will jointly cause the death of bacteria. Based on the above, Ag2S is used as a photothermal agent to produce antibacterial effects through near-infrared light irradiation, and synergizes with radionuclide therapy to inhibit melanoma recurrence and postoperative infection; in addition, PTT therapy can also achieve radionuclide therapy sensitization by increasing local tumor blood flow and improving tissue oxygenation.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] (1) The radionuclide nanomedicine hydrogel microneedles provided in this scheme are prepared by 32 P 32 PO4 3- Participate in biomineralization reaction to form Ca 32 P nanoparticles, which can be used to efficiently deliver Ca2+ to the tissue via microneedles 32 P nanoparticles are delivered in situ to the tumor site, effectively playing an anti-tumor recurrence role.

[0027] (2) The radionuclide nanomedicine hydrogel microneedles are 32 Ag2S nanoparticles were introduced into the mineralization process of P nanoparticles to prepare Ag2S@Ca 32 P can release Ag2S nanoparticles in response to the weakly acidic environment of the tumor. Under the irradiation of near-infrared light, its photothermal conversion efficiency can effectively kill bacteria, while effectively improving the hypoxic environment of the tumor, enhancing the therapeutic effect of the nuclide, and playing an antibacterial and wound healing role in the repair of melanoma defects.

[0028] (3) The radionuclide nanomedicine hydrogel microneedle Ag2S@Ca prepared in this scheme 32 The combination of radionuclide internal irradiation and photothermal effect of PMN can maximize the effect of inhibiting tumor growth and tumor recurrence.

[0029] (4) Nuclide nanodrug hydrogel microneedles Ag2S@Ca prepared in this scheme 32 P MN has excellent photothermal conversion efficiency, and the photothermal effect it produces has good antibacterial properties. It has a significant in vivo antibacterial effect when combined with photothermal therapy in vivo.

[0030] (5) Microneedles loaded with Ag2S@Ca 32 The drug delivery mode of P nanoparticles can effectively reduce the damage to the surrounding normal tissues or organs, and the carrier components are all non-toxic substances with good biocompatibility and degradability. In addition, the antibacterial, hemostatic, and cell adhesion-promoting effects of the microneedle tip component methacryloyl gelatin further promote wound healing.

[0031] (6) The preparation process of this scheme is simple and controllable, effectively avoiding the toxicity of the carrier, and has high drug loading and modification rate. The particle size of the radionuclide nanodrug prepared by the biomineralization method is uniform, with an average particle size of 162.5±7.2nm and good dispersibility. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0033] Figure 1 Ag2S@Ca obtained from Experimental Example 1 32 TEM images and particle size distribution of Ag2S@Ca32P. A is the TEM image of Ag2S@Ca32P at 50nm and 200nm scales, and B is the TEM image of Ag2S@Ca 32 Particle size distribution diagram of P;

[0034] Figure 2 The different concentrations of Ag2S@Ca obtained in Experimental Example 1 32 P is the photothermal conversion efficiency and photothermal stability diagram under near-infrared light irradiation; A is Ag2S@Ca 32 P is the photothermal conversion efficiency diagram under near-infrared light irradiation, B is Ag2S@Ca 32 Photothermal stability diagram of P under near-infrared light irradiation;

[0035] Figure 3 Ag2S@Ca obtained from Experimental Example 1 32 Photothermal imaging of P;

[0036] Figure 4 This is a graph showing the in vitro anti-tumor effect of nanoparticles of different components obtained in Experimental Example 1 on melanoma cells B16F10;

[0037] Figure 5 Ag2S@Ca obtained from Experimental Example 2 32 PMN array diagram and optical microscope diagram; A is Ag2S@Ca 32 Array diagram of PMN, B is Ag2S@Ca 32 Optical microscopy image of P MN;

[0038] Figure 6 Ag2S@Ca obtained from Experimental Example 2 32 PMN stress test diagram;

[0039] Figure 7Ag2S@Ca obtained from Experimental Example 2 32 P MN skin penetration depth hematoxylin & eosin staining light microscopy;

[0040] Figure 8 MN and Ag2S@Ca obtained from the test in Experiment 2 32 Photothermal imaging of P MN under near-infrared light;

[0041] Fig. 9 This is a graph showing the inhibition of Staphylococcus aureus by different MNs obtained from Experimental Example 2;

[0042] Fig.10 This is a diagram showing the therapeutic effects of different MNs obtained in Experimental Example 3 on the C57 mouse melanoma model;

[0043] Fig.11 This is a diagram showing the therapeutic effects of different MNs obtained in Experimental Example 4 on the C57 mouse melanoma recurrence model;

[0044] Fig.12 These are the therapeutic effect diagrams and bacterial infection diagrams of different MNs on the C57 mouse wound infection model obtained in Experimental Example 5. A is the therapeutic effect diagram of different MNs on the C57 mouse wound infection model, and B is the bacterial infection diagram of different MNs on the C57 mouse wound infection model. DETAILED DESCRIPTION

[0045] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0046] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and substance of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention.

[0047] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art; unless otherwise specified, the reagents used in the examples are commercially available.

[0048] Example 1

[0049] Preparation of radionuclide nanoparticles Ag2S@Ca 32 P

[0050] S1. Take 500 mg of bovine serum albumin (BSA) and dissolve it in 14 ml of ultrapure water. After ultrasonication, add 2 ml of 100 mmol / L silver nitrate (AgNO3), stir evenly, and adjust the pH to 12; then take 4 mL of 100 mmol / L sodium sulfide nonahydrate (Na2S·9H2O) and add it to the above solution. Heat and stir at 55°C for 4 hours, then incubate at 37°C overnight, and dialyze to obtain Ag2S nanoparticles;

[0051] S2, take equal volumes of ultrapure water and sugar-free DMEM in a beaker, add 200 mg BSA, take 2 mL of the Ag2S nanoparticles prepared in step S1 and add them, stir evenly; add 1 mCi / mL phosphorus [ 32 P] acid sodium salt solution, add 200 μL of 1 mol / L CaCl2 after ultrasound, incubate at 37 °C overnight, collect the precipitate after centrifugation and redissolve to obtain Ag2S@Ca 32 P nanoparticles.

[0052] According to the nanomaterial obtained in Example 1, Ag2S@Ca 32 The physicochemical properties and in vitro and in vivo pharmacokinetic and pharmacodynamic properties of P nanoparticles specifically include microscopic morphology, particle size, photothermal conversion properties, and in vitro cytotoxicity, among which the relevant nanomedicine obtained in Example 1 is specifically described.

[0053] Example 2

[0054] Preparation of radionuclide nano-drug hydrogel microneedles Ag2S@Ca 32 P MN

[0055] S1. Prepare a microneedle patch using a polydimethylsiloxane (PDMS) mold with a conical hole array. The microneedle size is 9 mm × 9 mm. All arrays include 100 needle tips. The diameter of the needle tip bottom is 250 μm and the needle length is 550 μm.

[0056] S2. Add 1 g of GelMA to 0.25% LAP to prepare a 20% methacrylated gelatin solution, and heat and dissolve it in a dark water bath at 60°C for 30 min.

[0057] S3, Ag2S@Ca 32 The PMN nanoparticles are dissolved in the solution in step S2 and stirred to obtain a Ag2S@Ca 32 The GelMA solution of P nanoparticles was injected into the microneedle mold, and after centrifugation, vacuum was drawn at 0.1 kPa for 10 min, and the above centrifugation and vacuum drawing steps were repeated 3 times. After discarding the excess liquid in the mold, it was dried in an oven at 37 ° C for 24 h and UV-cured to form the microneedle tip;

[0058] (4) 100 μL of 50% hyaluronic acid solution was injected into the microneedle mold as the base layer, and the solution was centrifuged and vacuumed, and then dried in an oven at 37° C. overnight. After demolding, the radionuclide nano-drug hydrogel microneedles were obtained.

[0059] According to the nuclide nano drug hydrogel microneedles obtained in Example 2, Ag2S@Ca 32 The apparent characteristics and anti-tumor and antibacterial properties of P MN specifically include microscopic morphology, photothermal conversion properties, in vivo and in vitro antibacterial effects, and in vitro anti-tumor recurrence effects, among which the relevant radionuclide nano-drug hydrogel microneedles obtained in Example 2 are specifically described.

[0060] Experimental Example 1

[0061] Investigation of the radionuclide nanomedicine Ag2S@Ca 32 P Characteristics

[0062] (1) Observation of Ag2S@Ca 32 Morphology of P nanoparticles

[0063] A small amount of sample was dropped onto a 400-mesh zinc grid covered with a carbon film, and then placed in a dryer to dry. After it was naturally dried, the morphology of the nanoparticles was observed under a transmission electron microscope Titan G2-F20.

[0064] The results are as follows Figure 1 As shown in A, the Ag2S@Ca 32 P nanoparticles are amorphous polymers under transmission electron microscopy.

[0065] (2) Determination of the particle size of nanoparticles using a dynamic light scattering particle size analyzer

[0066] Take Ag2S@Ca 32 The sample solution was placed in a Marlven Nano ZS instrument to detect the particle size of the nanoparticles.

[0067] The results are as follows Figure 1 As shown in B, Ag2S@Ca 32 The particle size of P is about 162.5±7.2nm, and it is a spherical nanostructure.

[0068] (3) Detection of different concentrations of Ag2S@Ca 32 PThe photothermal conversion efficiency at the same power

[0069] Ag2S@Ca@Mg ... 32 P nanoparticle solution, record the temperature change of the nanoparticle solution every 20S.

[0070] The results are as follows Figure 2As shown in A, with the Ag2S@Ca 32 With the increase of P nanoparticle concentration, the photothermal conversion efficiency is further enhanced.

[0071] (4) Detection of Ag2S@Ca 32 Photothermal stability of P

[0072] Ag2S@Ca with a concentration of 500 μg / mL was irradiated by 808 nm laser. 32 P nanoparticle solution, record the temperature change of the nanoparticle solution.

[0073] The results are as follows Figure 2 As shown in B, Ag2S@Ca 32 P nanoparticles were able to maintain photothermal stability during continuous illumination cycles, indicating that they could also maintain good stability during the treatment process.

[0074] (5) Detection of Ag2S@Ca 32 Photothermal imaging of P

[0075] 808nm laser was used to irradiate ultrapure water and Ag2S@Ca 32 P nanoparticle solution, record the temperature change of the nanoparticle solution every 20 seconds; and use an infrared thermal imager to capture the photothermal images of different nanoparticles every 1 minute.

[0076] The results are as follows Figure 3 As shown, compared with ultrapure water, Ag2S@Ca 32 P nanoparticles can heat up faster to the range of 40℃~50℃ at a fixed power.

[0077] (6) Investigation of radionuclide nanomedicine Ag2S@Ca 32 Killing effect of P on tumor cells

[0078] B16F10 cells were used as model cells, and the experimental groups were Ag2S, Ag2S@Ca 32 P, Ag2S@Ca 32 P+NIR (808nm near infrared radiation). After incubation for 48h, the supernatant was discarded and 5mg / mL MTT solution was added to each well and incubated in a cell culture incubator for 4h. The MTT solution was then discarded, 100μLDMSO solution was added to each well, and the absorbance (OD) of each well at 570nm was measured using an ELISA reader.

[0079] The results are as follows Figure 4 As shown, Ag2S, Ag2S@Ca 32 P, Ag2S@Ca 32 P+NIR showed concentration-dependent cytotoxicity. 32The nanomedicine in the P+NIR group worked together with radionuclides and photothermal therapy, thus showing the strongest tumor cell killing effect.

[0080] Experimental Example 2

[0081] Investigation of the radionuclide nano-drug hydrogel microneedle Ag2S@Ca 32 PMN Characteristics

[0082] (1) Observation of Ag2S@Ca with digital camera 32 PMN microneedle general morphology: Ag2S@Ca 32 P MN was placed on the table to observe the morphology of microneedles.

[0083] The results are as follows Figure 5 As shown in A, Ag2S@Ca 32 The PMn needle tips are arranged in an orderly manner on the basal layer, forming a regular and orderly microneedle array as a whole.

[0084] (2) Optical microscopy observation of Ag2S@Ca 32 PMN microneedle morphology: Ag2S@Ca 32 The P MN was placed under an upright microscope to observe the microneedle morphology.

[0085] The results are as follows Figure 5 As shown in B, Ag2S@Ca 32 The P MN tip width is 10 μm and the needle length is 550 μm.

[0086] (3) Electronic universal testing machine to detect Ag2S@Ca 32 PMN Mechanical Properties

[0087] The microneedle (tip side facing up) is placed on the test table. The mechanical sensor probe automatically compresses the microneedle at a speed of 0.5 mm / min. After reaching the maximum load (set to 55 N), it automatically stops running and records the applied force to draw a force-displacement curve.

[0088] The results are as follows Figure 6 As shown, the drug-loaded microneedle did not break even under a pressure of 0.55N / needle, indicating that the microneedle has excellent mechanical strength, which exceeds the 0.2N / needle required to pierce the skin and can penetrate the stratum corneum of the skin to achieve effective drug delivery.

[0089] (4) Observation of Ag2S@Ca 32 PMN skin puncture depth

[0090] Ag2S@Ca 32P MN was pierced into the back skin of hairless C57 mice, and the thumb was pressed for 2 minutes. The microneedle was removed, and the skin tissue at the microneedle insertion site was collected and fixed with 4% paraformaldehyde. After paraffin embedding, it was stained with hematoxylin & eosin, and the micropores formed after microneedle insertion were observed under a light microscope.

[0091] The results are as follows Figure 7 As shown, the slice staining results showed that the microneedle could form a needle hole with a length of about 263.5 μm on the mouse skin, indicating that the prepared microneedle could successfully penetrate the stratum corneum and enter the subcutaneous tissue.

[0092] (5) Detection of the photothermal conversion efficiency of microneedles containing nanoparticles of different preparations in vitro: MN, Ag2S@Ca 32 PMN was applied to the back skin of C57 mice. After continuous thumb pressure for 2 minutes, each group of microneedle patches was irradiated with 808nm laser, and an infrared thermal imager was used to capture the in vivo photothermal images of different microneedles every 1 minute.

[0093] The results are as follows Figure 8 As shown, compared with MN, Ag2S@Ca 32 P MN can heat up to 40℃~50℃ faster at a fixed power and has better photothermal conversion efficiency.

[0094] (6) Ag2S@Ca 32 In vitro antibacterial effect of PMN: The microneedles loaded with different preparations were immersed in 100 μL PBS solution and incubated with 100 μL Staphylococcus aureus suspension (1×10 8 / mL) and incubate for 3 hours. After incubation, dilute the bacterial suspension and plate it.

[0095] The results are as follows Fig. 9 As shown, Ag2S@Ca 32 The number of colonies after PMN+NIR treatment was significantly reduced, indicating that Ag2S@Ca 32 The photothermal effect produced by PMN has good antibacterial properties.

[0096] Experimental Example 3

[0097] Construction of a mouse melanoma model to investigate the radionuclide nanodrug hydrogel microneedle Ag2S@Ca 32 PMN treatment effect.

[0098] (1) Construction of mouse melanoma model: 1×10 6 B16F10 cell suspension with a concentration of 10 cells / mL was inoculated into the right back of male C57 mice to establish a melanoma model.

[0099] (2) Ag2S@Ca 32PMN treatment effect investigation: When the mouse tumor volume grows to 100mm 3 , and randomly divided them into 3 groups for microneedle application: Control, Ag2S@Ca 32 PMN, Ag2S@Ca 32 PMN+NIR. The long and short diameters of the tumors were measured with a vernier caliper within 15 days, and a tumor volume-time change graph was drawn.

[0100] The results are as follows Fig.10 As shown, compared with the control group, Ag2S@Ca 32 PMN、Ag2S@Ca 32 PMN+NIR group showed excellent tumor inhibition effect, among which Ag2S@Ca 32 The effect of P MN+NIR was the most significant, indicating that the combination of radionuclide internal irradiation and photothermal effect of the microneedle can maximize the effect of inhibiting tumor growth.

[0101] Experimental Example 4

[0102] Construction of a mouse melanoma recurrence model to investigate the radionuclide nanodrug hydrogel microneedle Ag2S@Ca 32 PMN treatment effect.

[0103] (1) Construction of mouse melanoma recurrence model: 1×10 6 The melanoma model was established by inoculating a B16F10 cell suspension with a concentration of 100 / mL into the right back of male C57 mice. 3 , 95% of the regional tumor tissue was removed and sutured.

[0104] (2) Ag2S@Ca 32 P treatment of recurrent tumors: C57 mice after 95% tumor tissue resection were randomly divided into 3 groups and treated with microneedles of different preparations: Control, Ag2S@Ca 32 PMN, Ag2S@Ca 32 PMN+NIR. The long and short diameters of the tumors were measured with a vernier caliper within 27 days, and the tumor volume was calculated and a tumor volume-time change graph was drawn.

[0105] The results are as follows Fig.11 As shown, compared with the control group, Ag2S@Ca 32 PMN, Ag2S@Ca 32 PMN+NIR group showed excellent anti-tumor recurrence effect, among which Ag2S@Ca 32 The effect of P MN+NIR was the most significant, indicating that the combined application of radionuclide internal irradiation and photothermal effect of the microneedle can maximize the effect of inhibiting tumor recurrence.

[0106] Experimental Example 5

[0107] Construction of a mouse wound infection model to investigate the radionuclide nanodrug hydrogel microneedle Ag2S@Ca 32 PMN antibacterial effect.

[0108] (1) Construction of mouse wound infection model: A 10 mm diameter circular full-thickness skin injury incision was made on the back of C57 mice, and 20 μL of Staphylococcus aureus suspension (1×10 8 / mL) was applied to the wound to establish a C57 mouse wound infection model.

[0109] (2) Ag2S@Ca 32 PMN antibacterial effect investigation: 1 hour after inoculation of bacteria, microneedles of different preparation groups were applied to the wound and divided into: Control, Ag2S@Ca 32 PMN、Ag2S@Ca 32 PMN+NIR. Before microneedle treatment and on days 0, 3, 7, and 12 after treatment, sterile cotton swabs were used to collect exudate from the wound and diluted for smearing.

[0110] The results are as follows Fig.12 As shown in A and 12B, compared with the control group, Ag2S@Ca 32 After treatment in the PMN+NIR group, wound infection was significantly alleviated, colony counts were significantly reduced, and wound healing was accelerated, indicating that radionuclide combined with photothermal therapy has a significant antibacterial effect in vivo.

[0111] The above is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments. For those skilled in the art, improvements and changes obtained without departing from the technical concept of the present invention should also be regarded as the protection scope of the present invention.

Claims

1. A nuclide nano-hydrogel microneedle, characterized in that: The nuclide nano hydrogel microneedle comprises a base layer and a needle tip layer, wherein the needle tip layer is composed of methacrylated gelatin loaded with nuclide nano drug Ag2S@Ca 32 P, the nuclide nanomedicine Ag2S@Ca 32 P includes core Ag2S nanoparticles, radionuclides 32 P-labeled calcium phosphate and bovine serum albumin coat.

2. The nuclide nano-hydrogel microneedle according to claim 1, characterized in that: The needle length of the nuclide nano-hydrogel microneedle is 550 μm, and the diameter of the base layer is 9 mm.

3. A method for preparing the nuclide nano-hydrogel microneedle according to any one of claims 1 to 2, characterized in that: The following steps are involved: S1, bovine serum albumin was dissolved in ultrapure water, and AgNO3 was added after sonication and stirred to mix well. After adjusting the pH to 12, Na2S·9H2O was added and heated and stirred, and then incubated overnight, and dialyzed to obtain Ag2S nanoparticles; S2, dispersing bovine serum albumin and the Ag2S nanoparticles obtained in step S1 into a mixture of ultrapure water and sugar-free DMEM, and adding phosphorus [ 32 P] acid sodium salt solution, CaCl2, incubate overnight and centrifuge, collect the precipitate and re-dissolve by ultrasonication 32 P-labeled Ag2S@Ca 32 P nanoparticles; S3, add methacrylic gelatin to the photoinitiator to prepare methacrylic gelatin solution, heat in a light-proof water bath to dissolve, and then add Ag2S@Ca 32 P nanoparticles were dissolved in methacrylated gelatin solution, injected into the microneedle mold, centrifuged and vacuumed, and then dried, and the needle tip was cured by UV; S4. Inject the base matrix into the microneedle mold with the needle tip solidified as the base layer, centrifuge and vacuumize, then dry, and demold to obtain the nuclide nano-hydrogel microneedle.

4. The preparation method according to claim 3, characterized in that: The molar ratio of AgNO3, Na2S·9H2O and CaCl2 is 1:2:1; the phosphorus [ 32 The radioactivity concentration of the sodium salt solution of 1 μg / mL was 1 mCi / mL.

5. The preparation method according to claim 3, characterized in that: The temperature of the heating and stirring in S1 is 55°C for 4 hours, and the temperature of the overnight incubation is 37°C.

6. The preparation method according to claim 3, characterized in that: The incubation temperature in S2 is 37°C.

7. The preparation method according to claim 3, characterized in that: The photoinitiator in S3 is LAP with a concentration of 0.25%, the mass concentration of the methacrylated gelatin solution is 20%, the water bath heating temperature is 60° C., the time is 30 minutes, and the drying time is 24 hours.

8. The preparation method according to claim 3, characterized in that: The base matrix in S4 includes a hyaluronic acid solution with a mass concentration of 50%.

9. Use of the nuclide nano-hydrogel microneedle as claimed in any one of claims 1 to 2 or the nuclide nano-hydrogel microneedle prepared by the preparation method according to any one of claims 3 to 8 in the preparation of drugs for inhibiting melanoma growth and postoperative recurrence, characterized in that: The drug needs to be combined with near-infrared light irradiation.

10. An application of the nuclide nano-hydrogel microneedle as claimed in any one of claims 1 to 2 or the nuclide nano-hydrogel microneedle prepared by the preparation method as claimed in any one of claims 3 to 8 in the preparation of drugs for preventing wound infection and promoting wound healing, characterized in that: The drug needs to be combined with near-infrared light irradiation.

Citation Information

Patent Citations

  • Soluble microneedle applied to boron neutron capture therapy as well as preparation method and application of soluble microneedle

    CN116327936A

  • Nuclide nano-drug for targeted therapy of breast cancer as well as preparation method and application of nuclide nano-drug

    CN116999581A

  • Functionalized nanoparticles and methods of use thereof

    US20130195752A1

  • Biodegradable microneedle patch for transdermal gene delivery

    US20230256219A1

Cited By

  • Radioactive freezing microneedle as well as preparation method and application thereof

    CN119818706A

  • Microneedle capable of loading antibiotics insoluble in water as well as preparation method and application of microneedle

    CN120204116A

  • Microneedles capable of loading poorly water-soluble antibiotics, preparation method thereof, and applications thereof

    CN120204116B